Compare BOLD & MNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | BOLD | MNY |
|---|---|---|
| Founded | 2018 | 2014 |
| Country | United States | Singapore |
| Employees | N/A | 240 |
| Industry | | |
| Sector | | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 57.5M | 58.9M |
| IPO Year | 2024 | N/A |
| Metric | BOLD | MNY |
|---|---|---|
| Price | $2.51 | $0.90 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | $4.00 | $4.00 |
| AVG Volume (30 Days) | ★ 2.3M | 68.7K |
| Earning Date | 05-06-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 32.47 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $19.58 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.96 | $0.78 |
| 52 Week High | $2.79 | $2.40 |
| Indicator | BOLD | MNY |
|---|---|---|
| Relative Strength Index (RSI) | 76.94 | 30.82 |
| Support Level | $1.08 | N/A |
| Resistance Level | $2.79 | $1.46 |
| Average True Range (ATR) | 0.14 | 0.13 |
| MACD | 0.08 | -0.02 |
| Stochastic Oscillator | 79.21 | 26.90 |
Boundless Bio Inc is a clinical-stage oncology company. It is focused on developing cancer therapeutics that address the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Using its proprietary Spyglass platform, the company identifies targets essential for ecDNA functionality, then designs and develops small-molecule drugs called ecDNA-directed therapies (ecDTx) to inhibit those targets. Its main ecDTx candidate under development, BBI-940, is a novel, oral, selective degrader that has demonstrated potent anti-tumor activity across a range of cancer cell lines and mouse xenograft models, including single-agent tumor regressions.
MoneyHero Ltd is a tech- and AI-powered personal finance aggregation and comparison platform and a digital insurance brokerage provider in Greater Southeast Asia. It operates in Singapore, Hong Kong, Taiwan and the Philippines. Its brand portfolio includes B2C platforms MoneyHero, SingSaver, Money101, Moneymax and Seedly, as well as the B2B platform Creatory. The company has four operating and reportable segments: Hong Kong, Singapore, the Philippines, and Taiwan. The Hong Kong segment generates the majority of the revenue.